These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2213908)

  • 1. Tumor infiltrating lymphocytes.
    Davidson AT
    J Natl Med Assoc; 1990 Sep; 82(9):612-3, 616. PubMed ID: 2213908
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
    Oldham RK
    Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
    [No Abstract]   [Full Text] [Related]  

  • 3. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 4. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
    Wolf JA; Grimm EA
    Curr Opin Oncol; 1989 Dec; 1(2):249-57. PubMed ID: 2489968
    [No Abstract]   [Full Text] [Related]  

  • 5. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
    Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
    Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy of malignant melanoma].
    Flageul B; Miclea JM; Bensussan A; Degos L
    Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver metastases from gastric carcinoma: report of a patient treated with adoptive immunotherapy (tumor-infiltrating lymphocytes plus interleukin-2 and subsequently local-regional lymphokine-activated killer cells plus interleukin-2).
    Fabbri L; Ridolfi R; Riccobon A; Maltoni R; Flamini E; Fedriga R; Flamigni A; Migliori G; Ortolani F; Calzolari F
    Tumori; 1995; 81(6):445-9. PubMed ID: 8804474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
    West WH
    Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of metastatic melanoma with interleukin-2].
    Chosidow O; Guillaume JC
    Ann Dermatol Venereol; 1992; 119(1):65-73. PubMed ID: 1373275
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphokine-activated killer lymphocytes: extramural clinical trials.
    Sniecinski IJ
    Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor-derived activated cells: culture conditions and characterization.
    Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
    Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin 2 in cancer therapy.
    Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
    Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of urologic tumors.
    Belldegrun A; Rosenberg SA
    Cancer Treat Res; 1989; 46():213-33. PubMed ID: 2577191
    [No Abstract]   [Full Text] [Related]  

  • 15. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer.
    Yannelli JR
    J Immunol Methods; 1991 May; 139(1):1-16. PubMed ID: 2040807
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
    Clark J; Longo DL
    Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
    [No Abstract]   [Full Text] [Related]  

  • 17. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 18. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
    Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive immunotherapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1994; 15():213-25. PubMed ID: 7779587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.